



THOMSON MEDICAL GROUP LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 199908381D)

-
- (A) **S\$25,000,000 5.50% NOTES DUE 2028 BY THOMSON MEDICAL GROUP LIMITED (TO BE CONSOLIDATED AND FORM A SINGLE SERIES WITH THE EXISTING S\$120,000,000 5.50% NOTES DUE 2028 ISSUED ON 31 MAY 2023 AND S\$30,000,000 5.50% NOTES DUE 2028 ISSUED ON 21 JULY 2023)**
- (B) **S\$20,000,000 5.25% NOTES DUE 2027 BY THOMSON MEDICAL GROUP LIMITED (TO BE CONSOLIDATED AND FORM A SINGLE SERIES WITH THE EXISTING S\$155,000,000 5.25% NOTES DUE 2027 ISSUED ON 13 MAY 2024)**

IN EACH CASE, TO BE ISSUED PURSUANT TO ITS S\$1,000,000,000 MULTICURRENCY DEBT ISSUANCE PROGRAMME

The Board of Directors of Thomson Medical Group Limited (the "**Issuer**") wishes to announce that it has launched and priced (1) S\$25,000,000 in aggregate principal amount of 5.50% notes due 2028 (to be consolidated and form a single series with the existing S\$120,000,000 5.50% notes due 2028 issued on 31 May 2023 and S\$30,000,000 5.50% notes due 2028 issued on 21 July 2023 (the "**Existing Series 003 Notes**")) (the "**Series 003 Tranche 003 Notes**" and, together with the Existing Series 003 Notes, the "**Series 003 Notes**") and (2) S\$20,000,000 in aggregate principal amount of 5.25% notes due 2027 (to be consolidated and form a single series with the existing S\$155,000,000 5.25% notes due 2027 issued on 13 May 2024 (the "**Existing Series 004 Notes**")) (the "**Series 004 Tranche 002 Notes**" and, together with the Existing Series 004 Notes, the "**Series 004 Notes**"). The Series 003 Tranche 003 Notes and the Series 004 Tranche 002 Notes will be issued by the Issuer pursuant to the S\$1,000,000,000 Multicurrency Debt Issuance Programme established by the Issuer on 28 June 2019 and updated on 21 April 2023 (the "**Programme**"). United Overseas Bank Limited has been appointed as the sole dealer in relation to the Series 003 Tranche 003 Notes and the Series 004 Tranche 002 Notes.

The principal terms of the Series 003 Tranche 003 Notes and the Series 004 Tranche 002 Notes are as follows:

Series 003 Tranche 003 Notes

Issue Size:	S\$25,000,000 (to be consolidated and form a single series with the Existing Series 003 Notes)
Issue Price:	100.00% of the principal amount of the Series 003 Tranche 003 Notes (plus accrued interest from and including 31 May 2024 up to but excluding 15 July 2024)
Denomination:	S\$250,000
Issuer's Redemption Option for Taxation Reasons:	At par, in accordance with the Programme

Issuer's Redemption Option in the case of Minimum Outstanding Amount:	At par, in accordance with the Programme
Noteholders' Redemption Option upon cessation or suspension of trading of shares:	At par, in accordance with the Programme
Interest:	5.50% per annum payable semi-annually in arrear
Maturity Date:	5 years from 31 May 2023
Security:	None

Series 004 Tranche 002 Notes

Issue Size:	S\$20,000,000 (to be consolidated and form a single series with the Existing Series 004 Notes)
Issue Price:	100.00% of the principal amount of the Series 004 Tranche 002 Notes (plus accrued interest from and including 13 May 2024 up to but excluding 15 July 2024)
Denomination:	S\$250,000
Issuer's Redemption Option for Taxation Reasons:	At par, in accordance with the Programme
Issuer's Redemption Option in the case of Minimum Outstanding Amount:	At par, in accordance with the Programme
Noteholders' Redemption Option upon cessation or suspension of trading of shares:	At par, in accordance with the Programme
Interest:	5.25% per annum payable semi-annually in arrear
Maturity Date:	3 years from 13 May 2024
Security:	None

The Series 003 Tranche 003 Notes and the Series 004 Tranche 002 Notes are expected to be issued on 15 July 2024 (subject to satisfaction of customary closing conditions) and listed on the Singapore Exchange Securities Trading Limited ("SGX-ST") on the market day after such issue.

The Series 003 Tranche 003 Notes and the Series 004 Tranche 002 Notes will constitute direct, unconditional and unsubordinated obligations of the Issuer and shall at all times rank *pari passu*, without any preference or priority among themselves, and at least *pari passu* with all other present and future unsecured obligations (other than subordinated obligations and priorities created by law) of the Issuer.

The Series 003 Tranche 003 Notes and the Series 004 Tranche 002 Notes will not be sold or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor (as defined in Section 4A of the Securities and Futures Act 2001 of Singapore (the “SFA”)) pursuant to Section 274 of the SFA, or (ii) to an accredited investor (as defined in Section 4A of the SFA) pursuant to and in accordance with the conditions specified in Section 275 of the SFA.

The net proceeds arising from the issue of the Series 003 Tranche 003 Notes and the Series 004 Tranche 002 Notes under the Programme (after deducting issue expenses) will be used for general corporate purposes of the Group, including refinancing of borrowings, financing potential acquisitions, strategic expansions, general working capital, capital expenditure and other investments of the Group.

Application will be made to the SGX-ST for the listing and quotation of the Series 003 Tranche 003 Notes and the Series 004 Tranche 002 Notes on the SGX-ST. Such permission will be granted when the Series 003 Tranche 003 Notes or, as the case may be, the Series 004 Tranche 002 Notes have been admitted to the Official List of the SGX-ST. The SGX-ST assumes no responsibility for the correctness of any of the statements made, opinions expressed or reports contained herein. Approval in-principle from, admission to the Official List of, and the listing and quotation of the Series 003 Tranche 003 Notes or the Series 004 Tranche 002 Notes on, the SGX-ST are not to be taken as an indication of the merits of the Issuer, its subsidiaries, its associated companies (if any), the Programme, the Series 003 Tranche 003 Notes or the Series 004 Tranche 002 Notes.

By Order of the Board

Wilson Sam

Executive Director and Group Chief Financial Officer

8 July 2024